Frequency Therapeutics Inc (KRRO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Frequency Therapeutics Inc stock (KRRO) is currently trading at $10.92. Frequency Therapeutics Inc PS ratio (Price-to-Sales) is 25.43. Analyst consensus price target for KRRO is $20.00. WallStSmart rates KRRO as Sell.
- KRRO PE ratio analysis and historical PE chart
- KRRO PS ratio (Price-to-Sales) history and trend
- KRRO intrinsic value — DCF, Graham Number, EPV models
- KRRO stock price prediction 2025 2026 2027 2028 2029 2030
- KRRO fair value vs current price
- KRRO insider transactions and insider buying
- Is KRRO undervalued or overvalued?
- Frequency Therapeutics Inc financial analysis — revenue, earnings, cash flow
- KRRO Piotroski F-Score and Altman Z-Score
- KRRO analyst price target and Smart Rating
Frequency Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Frequency Therapeutics Inc (KRRO) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Frequency Therapeutics Inc (KRRO) Key Strengths (1)
72.72% of shares held by major funds and institutions
Supporting Valuation Data
Frequency Therapeutics Inc (KRRO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -43.10%, a shrinking business
Very expensive at 25.4x annual revenue
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.2x book value
Supporting Valuation Data
Frequency Therapeutics Inc (KRRO) Detailed Analysis Report
Overall Assessment
This company scores 17/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (25.43), Price/Book (3.16) suggest expensive pricing. Growth concerns include Revenue Growth at -43.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -110.70%, Operating Margin at -1229.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -110.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -43.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KRRO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KRRO's Price-to-Sales ratio of 25.43x trades 49% below its historical average of 50.14x (26th percentile). The current valuation is 85% below its historical high of 169.64x set in Oct 2025, and 85% above its historical low of 13.73x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~72.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Frequency Therapeutics Inc (KRRO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Frequency Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 6M with 43% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 172% of revenue (11M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 43% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -18M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.54, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Frequency Therapeutics Inc.
Bottom Line
Frequency Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Frequency Therapeutics Inc(KRRO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. The company is headquartered in Cambridge, Massachusetts.